ReviewAnnual review of medicine2009
Extensively drug-resistant tuberculosis: a new face to an old pathogen.
Review in Annual review of medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- HPLC-DAD and UHPLC/QTOF-MS Analysis of Polyphenols in Extracts of the African SpeciesAntibiotics (Basel, Switzerland) · 2020Article
- Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia.BMC infectious diseases · 2019Article
- Immune regulation of miR-30 on theExperimental and therapeutic medicine · 2017Article
- Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1.The Journal of biological chemistry · 2017Article
- Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.Clinical and vaccine immunology : CVI · 2016Article
- Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains.Sensors (Basel, Switzerland) · 2016Article
- Tuberculosis vaccines and prevention of infection.Microbiology and molecular biology reviews : MMBR · 2014Review
- Exploration of piperidinols as potential antitubercular agents.Molecules (Basel, Switzerland) · 2014Article
- In silico prediction of protein-protein interactions in human macrophages.BMC research notes · 2014Article
- Targeting the "cytokine storm" for therapeutic benefit.Clinical and vaccine immunology : CVI · 2013Review
- Rapid direct testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin on nutrient and blood agar in resource-starved settings.Journal of clinical microbiology · 2012Article
- Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis.Antimicrobial agents and chemotherapy · 2012Article
- Article
- Article
- Antitubercular drug resistance in four healthcare facilities in North India.Journal of health, population, and nutrition · 2011Article
- Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.Biochemistry · 2011Article
- Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.The Journal of biological chemistry · 2010Article
- Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.Systems and synthetic biology · 2010Article
- A protecting group-free synthesis of deazathiamine: a step toward inhibitor design.Bioorganic & medicinal chemistry letters · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The presence and consequences of resistance to drugs used for the treatment of tuberculosis have long been neglected. The recent detection and recognition of widespread multiple-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have raised interest and concern among clinicians and public health authorities globally. In this article, we describe the current global status of drug-resistant tuberculosis. We discuss the development of resistance, current management, and strategies for control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.